Oppenheimer reaffirms its Outperform rating on Amgen Inc. (AMGN) with a price target of $380. The VESALIUS-CV trial showed that adding Repatha significantly reduced cardiovascular events in high-risk patients. Amgen also plans to sell Repatha at a cash price 60% lower than its current list price. The stock has a dividend yield of 3.23%.

Amgen continues to draw investor interest for its reliable dividend growth, raising payouts for 14 consecutive years. While acknowledging its potential, some believe certain AI stocks offer greater upside. For a free report on the best short-term AI stock, visit the provided link.

Read more at Yahoo Finance: Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study